HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

515.560

-16.828-3.16%

Number of Gainers:6

Number of Losers:26

Number of Flat:1

PE:- -

High:526.804

Open:526.804

Low:504.120

Close:532.388

Volume:37.26M

Turnover:983.79M

Market Cap:325.98B

Float Cap:291.58B

Loading ...

Akeso Biotech Jumps Over 8% at Open as AstraZeneca Makes US$2 Billion Strategic Investment in Summit, Ivonescimab Gains Backing from Top Pharma

Eli Lilly Has Already Spent Over $20 Billion This Year! CEO Says It Will Target Pharma "White Spaces" and Continue Pursuing Larger Acquisitions

AstraZeneca's $2 Billion Stake in Summit Signals Confidence in Akeso's Ivonescimab

CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B

CARsgen Says First Patient Dosed in China Phase I Registrational Trial of Ct1190b CAR-T for R/R LBCL

Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study

Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis

THOMSON REUTERS

Ascentage Pharma Group International's Chairman Buys 38,630 Shares

Ascentage Pharma Group International - Chairman Buys 38,630 Shares for Hk$1.2 Mln at Hk$29.95 Per Share on Sept 23-25

THOMSON REUTERS

Mabwell's Subsidiary Lianwei Chuangyuan to Bring In Investors, Aiming to Boost Innovative Drug Business

Everest Medicines Forms ESG Committee

Pharma ETF Rebounds Against the Tide as Device Giants Provide Support, Defensive Strength Draws Attention

ALPHAMAB-B (09966) Repurchases 58,000 Shares for HK$465,000 on September 28

Gansu State Farms Pharmaceutical Alkali Factory and Guangzhou Anxin Pharmaceutical Discuss Collaboration

Antengene-B (06996) Repurchases 90,000 Shares for HK$303,300 on September 28

GenFleet-B (02595) Spends HK$3.1855 Million to Repurchase 116,000 Shares on September 28

Dezhan Healthcare's Subsidiary Receives FDA Approval for Clinical Trial of Innovative Drug WYY026B Injection

Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together

Akeso Announces First Patient Enrolled in Global Phase Iii Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/BK1574/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":515.5602,"timestamp":1790928487328,"preClose":532.3884,"halted":0,"volume":37258611,"delay":0,"changeRate":-0.031609,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-16.828247,"latestTime":"10-02 16:00:00","open":526.80365,"high":526.80365,"low":504.12042,"amount":983786061.5,"amplitude":0.042607,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"pbRate":3.967371,"peRate":176.437057,"turnoverRate":0.001378,"increases":5,"decrements":27,"flats":0,"marketCap":325975381968,"floatMarketCap":291576058040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":526.80365,"amplitude":0.042607,"preClose":532.3884,"low":504.12042,"pbRate":"3.967371","latestPrice":515.5602,"volume":37258611,"delay":0,"open":526.80365,"prevYearClose":556.26263,"prevWeekClose":495.27,"prevMonthClose":532.388,"prevQuarterClose":532.388,"fiveDayClose":495.278,"twentyDayClose":515.473,"sixtyDayClose":490.453,"secType":"PLATE","market":"HK","turnoverRate":0.001378,"peRate":176.437057,"marketCap":325975381968,"floatMarketCap":291576058040,"timestamp":1790928487328,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":26,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131412257","title":"Akeso Biotech Jumps Over 8% at Open as AstraZeneca Makes US$2 Billion Strategic Investment in Summit, Ivonescimab Gains Backing from Top Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1131412257","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131412257?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:28","pubTimestamp":1790645294,"startTime":"0","endTime":"0","summary":"Akeso Biotech (09926) opened more than 8% higher, reaching 8.37% at HK$99.7 as of press time, with a turnover of HK$56.2558 million.On the news front, Akeso Biotech's overseas partner Summit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU0348735423.USD","LU1794554557.SGD","LU0348784397.USD","KCAI","BK1574","LU0348766576.USD","BK4588","09926","IE00B543WZ88.USD","LU2778985437.USD","KURE","LU0417516738.SGD","LU1720050803.USD","LU0417516902.SGD","LU0348827113.USD","LU2488822045.USD","BK4585","LU0348767384.USD","LU2399975544.HKD","LU0417516571.SGD","LU0561508036.HKD","BK1161","LU1961090484.USD","LU0540923850.HKD","LU0348825331.USD","IE00BPRC5H50.USD","VXUS","LU0348783233.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179659197","title":"Eli Lilly Has Already Spent Over $20 Billion This Year! CEO Says It Will Target Pharma \"White Spaces\" and Continue Pursuing Larger Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=1179659197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179659197?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:05","pubTimestamp":1790643950,"startTime":"0","endTime":"0","summary":"Eli Lilly & Co (NYSE: LLY) Chief Executive Dave Ricks said investors can expect the company to pursue larger deals, similar to its $7.8 billion acquisition of Centessa Pharmaceuticals Plc, as it...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","KCE","BK4585","BK1191","01477","BK1574","CALF","XMMO","MYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136239524","title":"AstraZeneca's $2 Billion Stake in Summit Signals Confidence in Akeso's Ivonescimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1136239524","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136239524?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:22","pubTimestamp":1790641354,"startTime":"0","endTime":"0","summary":"AstraZeneca has made a $2 billion strategic investment in Summit Therapeutics, pushing ivonescimab onto the center stage of global immuno-oncology competition. This deal not only serves as a major...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU2778985437.USD","LU0348784397.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0540923850.HKD","LU0561508036.HKD","09926","LU0348767384.USD","LU1720050803.USD","BK1574","LU0417516571.SGD","LU0348783233.USD","LU0348825331.USD","LU1961090484.USD","LU0417516902.SGD","LU1794554557.SGD","LU2488822045.USD","LU0348766576.USD","BK1161","IE00B543WZ88.USD","KURE","LU2476274720.SGD","LU0417516738.SGD","LU2399975544.HKD","LU0348735423.USD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146102396","title":"CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B","url":"https://stock-news.laohu8.com/highlight/detail?id=1146102396","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146102396?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:10","pubTimestamp":1790640613,"startTime":"0","endTime":"0","summary":"According to an announcement by CARSGEN-B (02171), CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registration clinical trial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","PSYK","BMED","IBBJ","IBBQ","BK1161","02171","BK1587","BK1574","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671707265","title":"CARsgen Says First Patient Dosed in China Phase I Registrational Trial of Ct1190b CAR-T for R/R LBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2671707265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671707265?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640058,"startTime":"0","endTime":"0","summary":"CARsgen says first patient dosed in China Phase I registrational trial of CT1190B CAR-T for R/R LBCLCARsgen dosed the first patient in China in a registrational Phase I trial of CT1190B for relapsed o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4XW7vr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02171","BK1161","BK1574","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265701","title":"Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671265701?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640030,"startTime":"0","endTime":"0","summary":"Ascletis says ASC50 cuts PASI score 48.9% in 28-day U.S. plaque psoriasis studyAscletis reported positive results from a 28-day U.S. proof-of-concept trial of ASC50 in plaque psoriasis.Results were pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4TYPnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108218509","title":"Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=1108218509","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108218509?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640027,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial of ASC50 in patients with mild to moderate plaque...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1161","BK1191","BK1515","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671657252","title":"Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671657252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671657252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA8SGRHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01672","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670776256","title":"Ascentage Pharma Group International's Chairman Buys 38,630 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2670776256","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670776256?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:39","pubTimestamp":1790609952,"startTime":"0","endTime":"0","summary":"Sept 28 (Reuters) - Ascentage Pharma Group International <6855.HK>::*CHAIRMAN BUYS 38,630 SHARES FOR HK$1.2 MILLION AT HK$29.95 PER SHARE ON SEPT 23-25*Further company coverage: 6855.HK* ((Reuters.Bri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nRSD2LvJTj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670255226","title":"Ascentage Pharma Group International - Chairman Buys 38,630 Shares for Hk$1.2 Mln at Hk$29.95 Per Share on Sept 23-25","url":"https://stock-news.laohu8.com/highlight/detail?id=2670255226","media":"THOMSON REUTERS","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670255226?lang=en_us&edition=fundamental","pubTime":"2026-09-28 22:46","pubTimestamp":1790606775,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134119945","title":"Mabwell's Subsidiary Lianwei Chuangyuan to Bring In Investors, Aiming to Boost Innovative Drug Business","url":"https://stock-news.laohu8.com/highlight/detail?id=1134119945","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134119945?lang=en_us&edition=fundamental","pubTime":"2026-09-28 22:08","pubTimestamp":1790604493,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) has announced that, in line with its strategic development plan and to further advance its innovative drug business while focusing on technological...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LNGR","BK1574","06978","02493","MEDX","159992","688062","IBBQ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140049460","title":"Everest Medicines Forms ESG Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=1140049460","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140049460?lang=en_us&edition=fundamental","pubTime":"2026-09-28 22:06","pubTimestamp":1790604372,"startTime":"0","endTime":"0","summary":"Everest Medicines (01952) has announced the establishment of an Environmental, Social and Governance Committee, effective from September 28, 2026.The ESG Committee shall consist of no fewer than...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119842469","title":"Pharma ETF Rebounds Against the Tide as Device Giants Provide Support, Defensive Strength Draws Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=1119842469","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119842469?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:55","pubTimestamp":1790596546,"startTime":"0","endTime":"0","summary":"On September 28, A-shares underwent a deep correction, yet the pharmaceutical sector once again demonstrated resilience, with the sector as a whole significantly outperforming the broader market,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","512170","BK1574","09939","562050","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194666412","title":"ALPHAMAB-B (09966) Repurchases 58,000 Shares for HK$465,000 on September 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1194666412","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194666412?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:28","pubTimestamp":1790594909,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that on September 28, 2026, it repurchased 58,000 shares for HK$465,000.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185291878","title":"Gansu State Farms Pharmaceutical Alkali Factory and Guangzhou Anxin Pharmaceutical Discuss Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1185291878","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185291878?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:51","pubTimestamp":1790592684,"startTime":"0","endTime":"0","summary":"Recently, the core R&D team from Guangzhou Anxin Pharmaceutical Co., Ltd. visited the Pharmaceutical Alkali Factory Co., Ltd. for an on-site tour and discussion. The company's leadership team, along...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180041245","title":"Antengene-B (06996) Repurchases 90,000 Shares for HK$303,300 on September 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1180041245","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180041245?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:20","pubTimestamp":1790590815,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has announced that on September 28, 2026, the company repurchased 90,000 shares for a total consideration of HK$303,300.For more major Hong Kong stock news, download the Zhitong...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194011215","title":"GenFleet-B (02595) Spends HK$3.1855 Million to Repurchase 116,000 Shares on September 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1194011215","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194011215?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:00","pubTimestamp":1790589620,"startTime":"0","endTime":"0","summary":"GenFleet-B (02595) has announced that on September 28, 2026, it spent HK$3.1855 million to repurchase 116,000 shares.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112995199","title":"Dezhan Healthcare's Subsidiary Receives FDA Approval for Clinical Trial of Innovative Drug WYY026B Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1112995199","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112995199?lang=en_us&edition=fundamental","pubTime":"2026-09-28 17:10","pubTimestamp":1790586629,"startTime":"0","endTime":"0","summary":"Dezhan Healthcare Company Limited (000813.SZ) has announced that its wholly-owned subsidiary, Beijing Honghui Xin Pharmaceutical Technology Co., Ltd., recently received notification from the U.S....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","000813","BMED","LNGR","BK1161","PSYK","BK0114","IBBQ","BK1574","BK0060","MDTX","MEDX","BK0239","BK4588","LABU","159992","BK4585","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132272624","title":"Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together","url":"https://stock-news.laohu8.com/highlight/detail?id=1132272624","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132272624?lang=en_us&edition=fundamental","pubTime":"2026-09-28 13:22","pubTimestamp":1790572929,"startTime":"0","endTime":"0","summary":"On the first trading day after the Mid-Autumn Festival (September 28), A-shares underwent a deep correction, with the Shanghai Composite Index falling nearly 2% at one point. Pharmaceutical assets...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","562050","MEDX","PTH","RSPH","BK0239","GDOC","LNGR","159883","BK1161","LGHT","AGNG","BK0187","BK1515","BK1100","09996","159938","HART","BK0188","BK1583","000513","IEIH","09939","MDEV","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670400169","title":"Akeso Announces First Patient Enrolled in Global Phase Iii Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2670400169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670400169?lang=en_us&edition=fundamental","pubTime":"2026-09-28 10:05","pubTimestamp":1790561139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUA2FCWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348767384.USD","LU0348783233.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0540923850.HKD","LU2476274308.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU1961090484.USD","KURE","LU0561508036.HKD","LU1794554557.SGD","LU0634319403.HKD","09926","LU1720050803.USD","LU2476274720.SGD","LU0348827113.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","LU0417516902.SGD","LU0348766576.USD","LU2399975544.HKD","LU0348784397.USD","BK1161","LU0348825331.USD","LU0417516738.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":199,"code":"91000000","status":"200"}]}}